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 INTRODUCTION 
The use of genome-wide approaches to analyze human DNA sequence in-
creases the likelihood of identifying disease-related variants. It is estimated that 
every whole-genome sequence contains around 10 to 50 putatively disease-
related variants, with up to five being of high clinical significance (Green, 
Rehm, et al. 2013). 
As large volumes of genomic data are generated for ever growing proportion 
of the population, guidelines for clinicians and researchers are needed on how 
to anticipate, address, and communicate incidental findings. To establish 
evidence-based guidelines regarding this matter open public discussions, em-
pirical research on stakeholders’ perspectives, comparison of different 
approaches of disclosure, as well as research on the predicted and reported 
impacts of communication of genomic research results to research participants 
are necessary (Jarvik et al. 2014).  
 
During the currently ongoing debate, several questions have been raised: 
 
 Should incidental findings be disclosed to research participants? 
 How much and which kind of information should be disclosed? 
 What is the optimal procedure for communicating incidental findings in 
a research practice? 
 What is the impact of disclosed information? 
 
This work addresses the issues and challenges of reporting incidental findings 
to the Estonian biobank participants. More specifically, the aims of the current 
research were to study the ethical, legal, and social implications surrounding the 
return of genomic research findings in the population biobank context, as well 
as to investigate perspectives of the general public and physicians involved in 
the recruitment of biobank participants. The conducted work established proce-
dures for communicating clinically significant research results to biobank 
participants, and for evaluating the effects of communicating such findings.  
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 1. REVIEW OF THE LITERATURE 
1.1. Types of research results 
1.1.1. Baseline assessment, aggregate and individual results 
Results of population studies, including population biobank-based, longitudinal, 
and epidemiologic studies, can be roughly divided into three classes: data 
generated in baseline assessments and laboratory analyses, aggregate research 
results, and individual research results. Aggregate results are obtained from 
analyses of a group of research participants, whereas individual research results 
concern a particular participant (Knoppers et al. 2013; Shalowitz & Miller 
2005). Communicating general results to research participants has been seen as 
a good practice (Beskow et al. 2012). Aggregate results can provide an over-
view of the use of participants’ data and frequently are published in a newsletter 
or on a website. Communication of such general results provides means for 
maintaining continuous contact with participants, educating participants about 
the research process, affirming the value of participation, and building trust. 
Policy guidelines recommend that participants should be notified as quickly as 
possible about baseline assessment results, clinically significant laboratory 
findings, and, when consent permits, other analytical results (Knoppers et al. 
2013).  
 
 
1.1.2. Incidental findings  
A research study may reveal an incidental finding, defined as “a finding con-
cerning an individual research participant that has potential health or repro-
ductive importance and is discovered in the course of conducting research but is 
beyond the aims of the study” (Wolf et al. 2008). Incidental findings can be 
distinguished from individual research results because, by definition, the former 
are outside the scope of the study and, therefore, may be outside the 
researchers’ focus areas or require additional clinical expertise (Christenhusz et 
al. 2013). When broad consent is used for genomic research, it may be difficult 
to distinguish individual research results from incidental findings (Wolf et al. 
2008). Discovery research is open-ended by nature, with multiple unforeseen 
research scopes. Thus, the entire collected data can be viewed as a research 
result or as an incidental finding. This thesis focuses on individual genomic 
research findings in the context of a population biobank in which all partici-
pants signed a broad consent form for unspecified future research and will refer 
to these findings as incidental findings.  
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 1.2. Debate on the return  
of incidental genomic findings  
There is an ongoing dispute whether the uncovering of incidental findings, 
collectively referred to as “the incidentalome,” is the future of, or a threat to, 
genomic medicine (Kohane et al. 2006; Biesecker 2013) (Figure 1). Some favor 
disclosure on the basis of autonomy, reciprocity, duty to warn, beneficence, and 
cost benefits (Fernandez et al. 2003; Shalowitz & Miller 2005; Knoppers et al. 
2013; Belsky & Richardson 2004; Green, Berg, et al. 2013) (Affleck, 2009). 
Others favor nondisclosure, citing nonmaleficence (“do no harm”), right not to 
know, diagnostic misconception, limited resources, and the research context in 
which testing is done (Forsberg et al. 2009; Solberg & Steinsbekk 2012; Cho 
2008; Nobile et al. 2013; Viberg et al. 2014; Kohane et al. 2006). Moreover, it 
is commonly unspecified what the concept “research results” entails. For 
example, whether only aggregate or individual results should be taken into 
account, and whether only validated or also preliminary research results should 
be considered (Miller et al. 2008). There also seems to be a tug of war between 
individual rights and beneficence, and collective responsibility and solidarity 
(Forsberg et al. 2009).  
 
 
1.2.1. Arguments in favor of disclosure 
Autonomy 
The ethical principle of respect implies that research participants are not treated 
as mere means to an end (Fernandez et al. 2003). Researchers have a duty to 
respect the autonomy and self-determination of participants and to acknowledge 
their “presumptive entitlement to information about themselves” by offering 
requested research results (Shalowitz & Miller 2005). Health-related infor-
mation would allow individuals to take control over their lives.  
 
Reciprocity 
Reciprocity regards the duty to promote trust between researchers and research 
participants (Knoppers et al. 2013). Based on this principle, participants are 
contributing to research and are entitled to receive something in return. 
Participants entrust researchers with their health information, putting them in a 
vulnerable position. Due to this entrustment, it can be argued that researchers 
have a duty to provide ancillary care (Belsky & Richardson 2004). It would be 
contradictory to point to the promise of genomics to deliver healthcare advances 
while ignoring detected variants of clinical importance (Biesecker 2013).  
 
Duty to warn 
Although researchers’ obligations are more limited than those of clinicians, 
certain obligations exist. Researchers have a duty to warn participants of 
foreseeable harm and minimize and prevent harm to research participants 
(Knoppers et al. 2013).   
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 Beneficence (“Do good”) 
Receiving risk information in a timely manner can reduce harms and increase 
benefits. This assumption is based on the premise that the to-be-disclosed 
findings impose substantial risk of a life-threatening condition that can be 
avoided or improved, or that the information could be important for repro-
ductive decision-making.  
 
Costs 
A few researchers have argued that, given the investments made in research, it 
would be wasteful to disregard or discard findings other than the primary 
findings. In order to maximize research output, the primary study protocol 
should include a plan to study the clinical utility of reporting incidental findings 
and the long-term outcomes of these “incidental cohorts” (Biesecker 2013).  
 
 
1.2.2. Arguments in favor of nondisclosure 
Nonmaleficence (“Do no harm”)  
Disclosure of incidental findings can be harmful if they have questionable 
analytic or clinical validity and/or no actionability. Research results on an 
individual level can have questionable analytical or clinical validity because 
research laboratories do not have the same standards of practice as clinical 
laboratories. Whereas researchers seek generalizable knowledge, clinicians seek 
to provide health information and clinical care. Incidental findings may be 
outside the area of expertise of the research team, which may be ill-equipped 
and  not licensed to provide health-related services and may require external 
clinical expertise to evaluate and communicate findings. There is a risk of 
causing a negative psychological response when participants do not know how 
to respond or interpret the complex information that is received.  
 
Autonomy (“Right not to know”) 
For some individuals, knowledge of a clinically significant genetic finding may 
be burdensome. Just as autonomy, the self determination of an individual, is an 
argument for providing the option of disclosing information, there must be a 
corresponding option for not knowing  (Andorno 2004).  
 
Research context 
The definitive purpose of research is to produce generalizable knowledge. 
Many pro-nondisclosure statements assume that participants should understand 
the intended output (i.e., common good and improved healthcare in the future) 
when contributing to biobank research. As articulated by Forsberg et al., “If 
potential donors are informed from the outset that there will be no direct 
personal gain from donating samples, and that individual results will not be 
returned, but that resources will be allocated to gaining as much general 
knowledge as possible, there need be no risk of individuals donating samples in 
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 the hope of personal benefit” (Forsberg et al. 2009). Furthermore, the patient-
physician relationship is different from the participant-researcher relationship. 
In the former, the patient’s primary intention is to get help or knowledge from 
the physician, who has the training and intention to provide care (Solberg & 
Steinsbekk 2012). In contrast, the primary intention in the research context is to 
maximize research output; there is no duty to disclose.  
 
Diagnostic misconception 
It is important to consider what the communication of results represents in 
context of the participant-researcher relationship and how it might create a 
conflict of interest (Cho 2008). Communicating clinically significant incidental 
findings to research participants may nurture the perception that participation in 
research is somehow related to receiving care. In clinical research, this undue 
expectation is referred to as “therapeutic misconception” (Henderson et al. 
2007). In genetic research, an equivalent phenomenon is called “diagnostic mis-
conception,” referring to the expectation of personal health-related information 
as a reward of the donation of biological material for research (Nobile et al. 
2013). Based on this perception, participants might expect that research results 
will be accompanied by clinical management. This perception could lead to an 
assumption that if no results are communicated, then no disease-related 
information was uncovered (Viberg et al. 2014). 
 
Limited resources 
Others have questioned the potential societal benefit of communicating inci-
dental findings. Some argue that the costs and unnecessary procedures 
associated with the return of incidental findings are arguments against their 
return (Kohane et al. 2006). In addition to the resources necessary for 
recontacting and validating the findings, communicating incidental findings is 
likely to pose a logistical challenge because most research establishments do 
not have the necessary infrastructure. This infrastructure includes the analytical 
power to find variants, and the procedures and manpower to disclose incidental 
findings in a manner that would improve medical care. Therefore, it could be 
argued that an obligation to return incidental findings would cause resources 
(time and money) to be spent on other than the primary goal of the research 
institute, thereby reducing the potential research outcome (Forsberg et al. 2009; 
Solberg & Steinsbekk 2012). 
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Figure 1. Arguments made supporting disclosure or nondisclosure of incidental findings.  
 
 
1.3. Biobanks and return of genomic research findings  
In the debate on the ethical, legal, and social implications of disclosure of 
incidental findings, the central dispute concerns the differences between clinical 
care and research. There are also a wide range of different research contexts. 
Here, we focus on large-scale population biobanks, which generally include 
individuals with a range of existing or previous conditions, but generally 
without an acute disease at the time of recruitment. Research is conducted using 
coded personal data and collected biological samples. When compared to 
medical research, population biobank research involves minimal risk to 
participants. However, genomic research has some unique considerations, as 
listed in the UNESCO International Declaration on Human Genetic Data 
(UNESCO 2003). Specifically, genomic data: 
 
 Can be predictive of genetic predispositions concerning individuals;  
 May have important impacts on the participant’s family, including 
offspring, extending over generations, and, in some instances, on the 
whole population to which the participant belongs; 
 May contain information of yet-unknown significance; and 
 May have cultural significance for persons or groups.  
 
Owing to these factors, genetic data are often considered to be more sensitive, 
leading to discussions of whether there should be specific legislation for genetic 
data and genetic research. Biobanks used for genomic research may be covered 
by biobank-specific legislation or by more general legislation (Knoppers et al. 
2015).  
 1.3.1. Biobank consent forms and legislation  
Biobanks, defined as “the organized collection of biological samples and 
associated data,” can vary in size, collection type, organization, management, 
funding, and use or purpose (Cambon-Thomsen 2004). Similarly, the consent 
forms and surrounding legislation vary (Knoppers et al. 2015). Traditionally, 
the informed consent procedure involves: 1) the adequate informing of partici-
pants as to what the research project involves, and 2) the obtaining of voluntary 
agreement to participate (NHGRI n.d.). Several factors complicate the consent 
process in population biobank research, such as the indefinite storage of 
samples and data, unspecified future research, recontact of participants, access 
to medical records, large-scale sharing of data, confidentiality and privacy, and 
access to research results.  
For large-scale prospective population biobanks intended for long-term use for 
unforeseeable future projects, broad consent is generally obtained. In broad 
consent, only the general scope of the future research is obtained, rather than 
acquiring new consent for each project separately. Ethical debate surrounds the 
appropriateness of using this type of consent (Master et al. 2012), but it has been 
shown to be the preferred approach by research participants (Simon et al. 2011). 
Alternative consent models include categorical/qualified consent and dynamic 
consent, which provide more choices to the research participant. Dynamic consent 
accounts for the dynamic nature of research possibilities over time (Kaye et al. 
2015; Steinsbekk et al. 2013). Dynamic consent utilizes information technology and 
allows participants to express their preferences, reassess their past decisions, and 
change consent in light of new circumstances and research possibilities.  
Recommendations on which elements should be included in a consent form 
for genomic research have been published (NHGRI n.d.). These elements include: 
the purpose of the research; description of procedures; potential risks and 
benefits; confidentiality and privacy; reimbursements, costs, and commer-
cialization; options for withdrawal from the research; alternatives to participation; 
and contact information of the investigator. Policies recommend that the 
“potential risks and benefits” section anticipate incidental findings and inform the 
participant of options for consultation with an external expert (e.g., genetic 
counselor) when appropriate. This section should also include a description of 
“any reasonably foreseeable risks,” such as an incidental finding that turns out to 
be a false positive or to have an unclear or ambiguous meaning. Knowledge of a 
finding with clinical significance and actionability can be considered as a benefit. 
Several biobanks, including the Estonian population biobank (more in 
Section 3.1), have been created over the last two decades. Unfortunately, the 
consent forms are not always “future proof”. In some cases, the original 
baseline consent form did not address the issues that now need to be covered. 
The ability to reidentify and recontact participants is not a given, but it is 
necessary to be able to link genetic findings with identifiable information 
(Cambon-Thomsen 2004). Some biobanks have completely anonymous data, 
making the recontacting of participants impossible or consent forms with a 
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 clause stating that the participant will not be recontacted. However, others argue 
that consent does not constrain researchers from their responsibility to respect 
participants and acknowledge their entitlement to information about themselves, 
particularly when that information has direct clinical implications (Shalowitz & 
Miller 2005). There have been a few suggestions for situations in which the 
initial consent form does not include options or information regarding incidental 
findings. Assuming that the form included consent for recontact, the “staged-
consent” recommendation involves recontacting and introducing the option to 
consent to receiving results (Knoppers et al. 2013; Appelbaum et al. 2014). 
 
 
1.4. Development of guidelines for disclosure  
of incidental findings 
1.4.1. Required elements of a finding to be reported 
Although the ethical, legal, and societal consensus is leaning towards favoring 
the return of some incidental findings, the challenge lies in developing a 
consensus on how this return should be carried out. Many proposals have listed 
the criteria necessary for an incidental finding to be reported (Wolf et al. 2008; 
Knoppers et al. 2013; Cassa et al. 2012; Fabsitz et al. 2010; Wolf et al. 2012; 
Thorogood et al. 2014). These proposals commonly include:  
 
 Analytic validity – Finding is accurately and reliably identified;  
 Clinical validity and significance – Finding reveals a well-recognized and 
significant risk of a serious condition; and  
 Utility or actionability – Recognized therapeutic or preventive inter-
ventions are available for the disease or condition inferred by the finding, 
or knowledge of the finding has the potential to change the clinical course 
of the disease or condition.  
 
Frameworks based on these so-called ACA criteria (Analytic validity, Clinical 
significance and Actionability) are intended to facilitate the grouping of 
findings into broad categories  taking into account the recommendations for 
disclosure (Wolf et al. 2008; Berg et al. 2011) (Figure 2). However, this 
application of the ACA criteria can be subjective and dependent on the pro-
viders’ relative value judgments of the criteria. Even experts disagree on how 
findings should be grouped based on the ACA criteria (Green et al. 2012). In 
response to these difficulties, methods have been developed to establish a more 
operational definition of clinically actionable findings (Goddard et al. 2013). In 
2013, a working group was formed by the American College of Medical Gene-
tics and Genomics (ACMG), and a preselected minimum list of 52 genes for 
return of incidental findings was created for the clinical setting, referred to as 
the ACMG recommendations (Green, Berg, et al. 2013). The ACMG minimum 
list includes known deleterious or presumed deleterious variants of medically 
actionable conditions, which are equivalent to Bin 1 in Figure 2. 
18
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The ACMG recommendations for reporting have been implemented in 
several countries, including Estonia (Anon n.d.). However, as yet there is no 
international consensus in neither clinical nor research contexts. There has been 
discussion on developing a European consensus document because genomic 
research projects often are funded and coordinated internationally and involve 
participants from several countries (Hehir-Kwa et al. 2015). Currently, the 
decision whether the results will be communicated depends on national policies, 
guidelines, and ethics committees. This approach can be problematic from the 
participants’ viewpoint, who might be treated differently from one another in 
terms of feedback even within the same research project. Another discussion 
addresses whether recommendations such as the ACMG recommendations 
proposed by Green et al. (Green, Berg, et al. 2013) can be applied in a research 
setting, given the divergent aims and guiding principles between research and 
clinical care (Jarvik et al. 2014).  
 
Figure 2.  A proposed system for “binning” of incidental findings (Adapted from Berg 
et al. 2011). N/A – not applicable; VUS – variant of uncertain significance; PGx – 
pharmacogenomics; SNPs – single nucleotide polymorphisms; Genes listed as examples 
and associated conditions: BRCA1/2 – Hereditary breast and ovarian cancer; MLH1 and 
MSH2 – Lynch Syndrome; FBN1 – Marfan Syndrome; NF1 – Neurofibromatosis type 
1; APOE – Alzheimer's disease; SOD1 – Amyotrophic lateral sclerosis (ALS). 
1  Reporting through shared decision making with an appropriate healthcare specialist 
if elected by the patient. 
2  Variants in genes with unknown implications cannot be considered deleterious. 
3  By definition risk SNPs or PGx variants are either present or absent. 
4  Variants in genes with unknown clinical implications would not be reported, but 
would benefit from further research.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1.4.2. Procedures for disclosing incidental findings 
Due to great variability among biobanks (Section 1.3.1.), it is unlikely that a 
single approach would be suitable for all settings (Bledsoe et al. 2012). Four 
different approaches are used internationally for the return of results to research 
participants (Knoppers et al. 2015; Thorogood et al. 2014): 
 
 Only panels of specific genes or targeted sequences are allowed, to 
reduce the potential for incidental findings;  
 Results can only be returned when they meet the ACA criteria;  
 An ad hoc case-by-case determination; and 
 No return.  
 
There seems to be a consensus that neither a complete nondisclosure nor a 
complete disclosure policy is appropriate. Instead, which findings should be 
reported to participants, and what the procedure for communication should be 
depends on the particular situation. There are some practical requirements 
involved in the return of results, such as developing a method to recontact 
participants, acquiring consent for the return of results, establishing a frame-
work for the procedure of disclosing results, and separately validating findings 
considered for disclosure. Findings to be disclosed must be analytically valid: 
that is, confirmed in a certified lab. This confirmation can be challenging, as not 
all research findings are available as tests in clinical labs. In such cases, it is 
recommended that the finding be labeled as a research finding and not a clinical 
finding.  
Recommendations for biobanks are that they set up a process for com-
municating incidental findings and address the associated risks and limitations in 
the initial consent process. The consent form should include limitations on which 
kind of information is reported and what is left out. Specifically, the form should 
indicate that there may be other incidental findings that are not reported and some 
clinically significant findings that are not recognized or are ambiguous in 
meaning (NHGRI n.d.). Many newly established biobanks address the possibility 
of uncovering incidental findings in their policies and provide detailed 
descriptions of the communication of incidental findings in their initial consent 
forms (Fullerton et al. 2012; Johnson et al. 2012; Fabsitz et al. 2010).  
The method of grouping findings based on categories is applied in the 
qualified disclosure consent procedure (Christenhusz et al. 2013; Bredenoord et 
al. 2011). In this procedure, only findings with confirmed clinical utility and 
treatment or prevention possibilities qualify for routine disclosure. Research 
participants can indicate their preferences, including their right not to know, for 
certain categories. This approach is known as elective disclosure. The goal of 
binning and categorizing is to set limits and increase patient autonomy by 
constraining the decision process (Levy 2012). When the choice is between 
nondisclosure and full disclosure, the general response tends to be a “reflexive 
response to learn everything,” which might not be a particularly informed 
20
 choice (Roche & Berg 2015). The principle of qualified disclosure is also 
applied in dynamic consent method (Kaye et al. 2015; Steinsbekk et al. 2013).  
The capacity of a DNA sequence analysis to detect disease-causing varia-
tions in the genome depends on the analysis and filtering techniques that are 
used. Therefore, the question of the debate should perhaps be rephrased to 
whether there should be a deliberate search for clinically significant findings 
(Schuol et al. 2015). The search for incidental findings based on a pre-
determined list of clinically significant variants, known as “opportunistic 
screening,” has been viewed as unjustified in research practice because it has 
“the potential to undermine the research enterprise” (Presidential Commission 
for the Study of Bioethical Issues 2013). 
 
 
1.5. Empirical research on disclosure  
of return of results  
1.5.1. Stakeholders’ perspectives, preferences and attitudes 
It is valuable to know the perceptions and attitudes of stakeholders towards 
biobanking, genetic research, and communication of incidental findings. As 
mentioned in Section 1.2.1, some argue that research results should be offered 
as a motivator for participation and of trust between researchers and partici-
pants. Others argue that participation in research with the primary motivation of 
personal gain is based on the wrong premises, as the research goal should be the 
collective benefit for future patients (Solberg & Steinsbekk 2012). Empirical 
research, however, indicates that participants’ motivations often are related to 
individual benefits generally through the gain of knowledge from health-related 
information (Nobile et al. 2013). Participants are interested in receiving results. 
In some cases, they even expect to receive something in return for participation 
(Bollinger et al. 2012; Middleton et al. 2015). These expectations are likely 
influenced by personal beliefs and trust towards the research institution, but are 
also dependent on the information provided during the consent process of 
recruitment and their comprehension of such information.  
Diverse preferences are observed among members of the public, varying 
from wanting to know everything possible to no interest in incidental findings 
(Regier et al. 2015). The high preference for information is not limited to 
conditions that fulfill the ACA criteria, as there is interest in results with unclear 
treatment options or no known health consequences (Meulenkamp et al. 2010; 
Bollinger et al. 2012; Facio et al. 2013; Bennette et al. 2013). Other factors 
beyond actionability, clinical utility, or even clinical significance are potentially 
viewed as relevant by participants. While participants desire to learn about a 
range of genomic information, significant differences have been shown between 
the categories of findings (Facio et al. 2013). Attitudes towards receiving results 
on an actionable conditions and carrier status for Mendelian diseases were 
significantly higher than interest towards findings related to non-actionable 
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 conditions and findings of uncertain significance. These results highlight the 
significance of a more refined choice than disclosure-nondisclosure, and need to 
consider preferences beyond the dimensions of treatability and clinical utility. 
The public acknowledges that the medical relevance of incidental findings is 
subjective and prefers to have several options, similar to that offered by 
qualified disclosure or dynamic consent (Townsend et al. 2012).  
Meanwhile, the public recognizes the practical problems associated with the 
return of incidental findings (Bollinger et al. 2012; Townsend et al. 2012). 
Middleton et al. reported that although most people thought that findings should 
be made available if participants express interest, only a minority thought it was 
reasonable for researchers to search actively for incidental findings if doing so 
might compromise their research (Middleton et al. 2015). This finding is in 
agreement with the ethical arguments made in Section 1.2.2 regarding the main 
aims of research.  
Compared to the public, the views of genetic researchers and clinical 
professionals in the genetic health profession are more conservative, possibly 
due to an anticipation of an increased workload when being invited to help with 
the interpretation of findings and counselling (Middleton et al. 2015).  
 
 
1.5.2. Predicted and reported effects of disclosure 
Studies investigating participants’ understanding and interpretation of genomic 
information, and the psychosocial and behavioral impacts of personal genome 
information have commonly been conducted among patients in clinical contexts 
(Bennette 2013) or direct-to-consumer genetic testing (DTCGT) service users 
(Bloss et al. 2011; Bloss et al. 2013; Francke et al. 2013; Kaufman et al. 2012). 
Although individuals purchasing the commercially available genomic testing 
service likely do not represent the population at large (with adult, white non-
Hispanics, older adults, people with higher incomes and postgraduate degrees 
being overrepresented (Kaufman et al. 2012)). These DTCGT service users are 
generally healthy individuals similarly to the population study participants, in 
contrast to patients undergoing testing in a clinical setting likely due to a 
specific clinical concern. 
The arguments for non-disclosure include the potential for harm. While 
anxiety is a key consideration among all stakeholders it may be more exag-
gerated among professionals compared to the public (Townsend et al. 2012). 
Studies conducted among DTCGT service users have suggested that genomic 
risk predictions for common complex diseases (low-impact variants affecting 
risk of common diseases) had no adverse psychological, behavioral or clinical 
effects on the study subjects short-term or long-term (Bloss et al. 2011; Bloss et 
al. 2013). Lack of evidence for long-term adverse response was also reported in 
a study investigating response to positive findings for hereditary breast and 
ovarian cancer genes, BRCA1 and 2 (highly penetrant autosomal dominant), 
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 among DTCGT service users (Francke et al. 2013), as well as in a population-
based study (O’Neill et al. 2015).  
Another argument against the disclosure of incidental findings to healthy 
individuals has been the potential for overwhelming the health care system with 
unnecessary procedures (McGuire & Burke 2008). However, results from Bloss 
et al. suggest that although about half of the respondents intend to undergo 
screening or medical tests, only a minority reported of actually doing so (Bloss 
et al. 2011). Similarly, an overestimation can be seen in respect to sharing 
results with physicians where one third of respondents reported sharing their 
DTCGT results with a physician, compared to the more than three quarters who 
predicted doing so (Kaufman et al. 2012).  Thus, the potential additional burden 
to the healthcare system may not be as large as anticipated. 
Published empirical research on the effect of disclosing individual findings 
to research participants is limited. However, a few ongoing research projects 
have been specifically designed to pilot the application of genome sequencing 
in medicine in order to establish evidence-based practice of genomic medicine. 
These include the ClinSeq and MedSeq projects launched in 2009 and 2014 
respectively (Lewis et al. 2016; Vassy et al. 2014).  
Within the MedSeq study, the perceived utility of whole genome sequencing 
(WGS) was investigated (Lupo et al. 2016). The majority of participants per-
ceived some utility of WGS for health-related decision making, while another 
23% saw utility also in relation to reproductive choices and end-of-life 
planning, items that can be considered to be related to personal utility. Close to 
a fifth of the respondents, however, were skeptical regarding the utility of WGS 
results in general. This skepticism seemed to be associated with limited trust 
towards the ability to translate WGS information in clinical practice.      
In a recent report on the ClinSeq study, the reactions of participants to 
actionable sequencing results were reported to be positive or neutral by the 
majority of respondents (Lewis et al. 2016). In contrast to the results reported in 
DTCGT context (Kaufman et al. 2012), high rates of disclosure of findings to 
family members and physicians were reported in the ClinSeq study. This 
difference could be either due to the type of findings reported or due to diffe-
rences in study settings. Although majority did not report changes to healthcare 
in response to sharing the genomic information, participants valued receiving 
the results and the majority of them were interested in receiving results in the 
future.   
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 2. AIMS OF THE STUDY 
The aims of the current study were as follows: 
1. To evaluate the ethical, legal, and social implications and logistical 
challenges related to the return of individual genomic research results to 
Estonian population based biobank participants of the Estonian Genome 
Center, University of Tartu; 
2. To investigate the perspectives and attitudes among the Estonian general 
public and physicians in regard to disclosing genomic information;  
3. To establish a process for communicating individual genomic research 
results to population biobank participants; and 
4. To investigate preferences for the return of results and to evaluate the long-
term effects of disclosing an incidental genomic finding.   
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 3. MATERIALS AND METHODS 
3.1. Estonian Genomic Center  
of the University of Tartu (EGCUT)  
(Ref. V) 
The Estonian Biobank, founded in the year 2000, is a population-based biobank 
of the EGCUT. Its main objectives, as stated in the Human Genes Research Act 
(HGRA), include the development of genetic research, collection of health and 
genetic information on the Estonian population, and implementation of genetic 
research results for the benefit of public health (Riigikogu 2000). The cohort 
size of 52,000 is about 5% of the adult population of Estonia from whom 
samples and health data were collected (Ref. V, Figure 1). A computer-assisted 
baseline survey was amended with modules added over the years (Ref. V, Table 
1) as new projects were started. The final version of the questionnaire included 
~330 questions. 
 
 
3.1.1. Biobank legislation and consent (Ref. VI) 
The HGRA was passed by the Estonian Parliament in 2000 (Riigikogu 2000). 
The HGRA regulates the maintenance and oversight of biobanks, the use of 
biobank data and samples stored in the repository, and the protection of rights 
of participants. As required by the HGRA, the participation is on a voluntary 
basis and through signing the EGCUT broad consent form. Some aspects of the 
HGRA and the broad consent form, were both crucial for the data collection and 
application for specific research purposes. These aspects are described in Ref. 
VI and include the ability to recontact participants, the ability to collect additio-
nal data from existing registries and databases, and the right of participants to 
be informed or not informed of the data that are collected and generated.      
 
 
3.1.2. Recruitment and public engagement 
Participant recruitment began in 2002. Recruitment was conducted via a 
network of primary care physicians (PCPs) throughout Estonia (Ref. V, Figure 
2) and two recruitment centers, in Tallinn (primary) and Tartu (alternative). The 
recruiter network included 454 PCPs and 186 nurses. Overall, 56% of registered 
PCPs were involved with the project. 
The EGCUT has investigated the general public’s opinion and awareness of 
the biobank since 2001 (Metspalu 2004; Kaasik et al. 2011). A cohort of 1000 
individuals between the ages of 15 and 74 years was surveyed through 
computer-assisted telephone interviewing. According to the last poll in 2014, 
73% of Estonians stated that they were aware of the activities of the EGCUT. 
Among them, 70% strongly supported the project and only 1% were against the 
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 project (Figure 3). Since the establishment of the biobank, three of the 52,000 
participants have applied for the destruction of their tissue samples; two 
participants have prohibited the supplementation, renewal, and verification of 
their state of health descriptions stored in the biobank; and 26 participants have 
applied for deletion of the key that enables decoding.  
 
Figure 3. Public opinion and awareness of the EGCUT. Results as per the TNS Emor 
survey conducted since 2001 until 2014. Adapted from Kaasik et al. (Kaasik et al. 
2011).  
 
3.1.3. Recontacting and linking (Ref. VI) 
The value of a biobank depends on the information accompanying the bio-
logical samples. Regularly updating health information increases the biobank’s 
usefulness, enables researchers to conduct longitudinal and prospective studies, 
and allows new questions to be addressed that were not supported by the 
original database. Two means of acquiring new information about participants 
are through recontacting and through acquiring information from other existing 
databases and registries.  
The HGRA permits the EGCUT to recontact biobank participants. Two 
recontacting projects were conducted. In the first project, participants were 
approached through their PCPs, and the response rate was 57.2%. In the second 
project, participants were invited though regular mail, and the response rate was 
41.1% (Ref. VI). Overall, close to 2000 participants were reexamined.  
Estonia, like many Nordic countries, has a long tradition of national 
registries. The HGRA permits the EGCUT to obtain additional information 
from existing databases and registries and link it with the EGCUT’s biobank. 
This opportunity has been used regularly since 2010 (Ref. VI, Figure 1). Data 
were obtained from existing registries and databases for almost all participants 
(Ref. VI, Table 1).  
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 3.2. Research conducted and research results (Ref. V) 
Various research projects are conducted using the data and samples of the 
EGCUT. As of 2016, whole-exome and whole-genome sequencing data were 
available for 2,500 and 2,500 participants, respectively, with genome-wide 
genotype data being available for an additional 15,000 participants. Research 
results are obtained locally, or by collaborators who share results with the 
EGCUT once the project ends (Ref. V). The EGCUT database includes in 
addition to baseline assessments and lab analyses, general results, and 
individual research results or incidental findings. This thesis focuses on the 
latter. 
 
3.2.1. Surveying PCPs  
PCPs who were actively involved with participant recruitment for the EGCUT 
were surveyed. The survey was designed to get insight into their experience and 
knowledge in genetics, their perspectives regarding the use of genomic 
information in healthcare practice, and their interest in additional training on 
genetic testing (Ref. II, Appendix). The anonymous electronic survey was 
composed in an online survey program (Survey Monkey). The Statistical 
Package for the Social Sciences (SPSS) was used to analyze results.    
 
 
3.2.2. Return of an incidental finding (pilot project)  
For this thesis, we disclosed 16p11.2 CNV carrier status to EGCUT partici-
pants. 16p11.2 600-kb breakpoint 4 (BP4) to breakpoint 5 (BP5) deletion and 
reciprocal duplication carriers were identified in the EGCUT cohort. In a 
previous study, Jacquemont et al. investigated and characterized carriers of 
16p11.2 copy-number variations (CNVs) using clinical information available in 
the EGCUT database (Jacquemont et al. 2011). 16p11.2 CNVs are syndromic 
CNVs that are commonly associated with neurodevelopmental disorders and 
body mass index imbalance. Extensive phenotypic variability is observed 
between carriers, with phenotypes ranging from almost asymptomatic to 
severely affected. 
In agreement with the known population prevalence of 16p11.2 600-kb BP4-
BP5 CNVs, four deletion carriers (0.05%) and seven duplication carriers 
(0.09%) were identified in the Estonian set (Jacquemont et al. 2011). The 
carriers of 16p11.2 CNVs identified were invited back for follow-up investi-
gations (Ref. III) and characterized using the standardized clinical and neuro-
psychological protocol developed for the characterization of 16p11.2 syndro-
mes among individuals who had been ascertained through clinical cohorts 
(Jacquemont et al. 2011; Zufferey et al. 2012). Procedures for recontacting 
participants and communicating results are described in Section 5.2.1 and Ref. 
IV.  
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 A survey was developed to investigate the impact of disclosure of 16p11.2 
CNVs (Ref. IV Supplementary material S4). The survey was constructed 
considering the outcome domains considered useful by healthcare professionals 
and patients (Payne et al. 2007; McAllister et al. 2011). The survey was edited 
after a review by working group members. Most survey questions were multiple 
choice questions with answers on a five-point Likert Scale (5: agree, 4: slightly 
agree, 3: unsure, 2: slightly disagree, 1: disagree). The sample set was too small 
for statistical analysis.  
 
 
3.2.3. Surveying the public  
To investigate the general public’s attitudes towards the use of genomic 
information in healthcare, surveys were conducted by the polling agency TNS 
Emor in 2011, 2013, and 2014 (Leitsalu et al. 2012). Each year, ~1000 Estonian 
residents between the ages of 15 and 74 years were surveyed. The sample was 
composed to be proportional to the population structure with respect to age, sex, 
region, and nationality. Computer-assisted telephone interviewing was used for 
the survey. SPSS was used for data analysis. The survey included several 
questions adapted from previously conducted similar studies (McGuire et al. 
2009; Cherkas et al. 2010; McBride et al. 2010; Bloss et al. 2011). Topics 
investigated in the 2011 survey included the knowledge of genetics, attitudes 
towards genetic testing, predicted effects on health behavior, motivators for and 
barriers against testing, funding of testing, and data access. In 2013 and 2014, 
most questions were repeated (attitudes towards genetic testing, predicted 
effects on health behavior, and motivators for and barriers against testing) for 
monitoring purposes, and a question was added about first-line genomic 
counseling. 
 
3.3. Ethics 
For all of the projects in this thesis involving recontacting and/or surveying of 
participants or physicians, ethical approval was obtained from the Research 
Ethics Committee of the University of Tartu.  
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 4. RESULTS AND DISCUSSION 
4.1. Communicating genomic findings in theory 
4.1.1. Physicians’ perspectives (Ref. II) 
An anonymous electronic survey was sent to 130 PCPs, of whom 64 responded. 
Respondents represented a range in terms of years in practice and location. 
Among respondents, expectations from genetics in primary care were high: 
96.4% believed that predictive genetic testing will improve health care, 73.3% 
believed that predictive genetic testing will be used in their practice in the next 
5 years (i.e. by 2014), and 75% reported having patients who show interest in 
their genomic health data (Ref. II, Table 2).  
Several questions addressed the conditions for which the physician would 
feel comfortable reporting genetic findings. Whereas 36.4% would report 
genetic findings under any circumstance, a majority would inform the patient 
under the condition that the finding is preventable (43.6%) or treatable (9.1%). 
There was a disagreement between responses for generic criteria questions 
versus specific conditions. Over 70% of respondents who selected the criterion 
to report only preventable or treatable conditions were willing to report about 
genomic findings conferring risk for Alzheimer or Huntington disease.     
In sharing genomic information, PCPs expressed that they were most 
concerned by the “unnecessary stress caused by the risk predictions” (ranking 
average: 2.18) and least concerned with “stigma” (ranking average: 3.85) (Ref. 
II, Table 5). Responses to most options followed a normal distribution, although 
responses for “patient’s autonomy and right not to know” (ranking average: 
3.04) and for “discrimination by life insurance and other companies” (ranking 
average: 3.18) fell into two extremes (Figure 5.). Overall, three major themes 
emerged from the survey results: eagerness to apply genomic information into 
practice, apparent disparity between enthusiasm of using genomic information 
and readiness to do so, and willingness to improve the knowledge base in 
genetics and genomics.  
This study had a possible ascertainment bias. Although survey respondents 
represented ~8% percent of all 804 PCPs in Estonia, they likely did not 
represent the general population of PCPs. They probably represented a group of 
physicians who were likely to have a more positive attitude towards the role of 
genetics in healthcare. Nevertheless, this finding indicated to us that there was a 
group of physicians that could be engaged in a pilot project of personalized 
medicine.  
A similar survey was conducted among 40 healthcare practitioners (PCPs 
and nurses, oncologists, cardiologists, and endocrinologists) in 2015 by the 
Ministry of Social Affairs as part of the Feasibility Study for Personalized 
Medicine in Estonia (FSPME) (Anon 2015). Results of this survey were in line 
with the previous findings. In general, healthcare practitioners considered 
broader implementation of genetic information to be relevant and necessary, 
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 and they were interested in training that would provide them with basic 
knowledge of genetics. Some commonly expressed fears included: 1) an 
increase in an already overly large workload, and 2) unnecessary worry on the 
part of patients, which would translate into a greater workload for the healthcare 
system.   
It may be challenging to withhold information of medical significance once 
uncovered. Thus, it is necessary to have guidelines, which should preferably be 
more specific than categorical (i.e. a list of conditions). Ideally, the analysis 
pipeline would filter out findings that are not recommended to be returned, to 
avoid such findings from being released to the physician. The need for specific 
guidelines is supported by both Ref. I and the healthcare professionals surveyed 
in the FSPME. Physicians expressed several needs, including reasonably 
established processes, activities, and roles, and preparation of all stakeholders. 
These steps would hopefully address commonly debated questions about what 
stakeholder responsibilities are, who needs genetic testing (and to what extent), 
who decides the necessity of making genetic tests, who is responsible for 
interpreting test results, and how results should be interpreted (Anon 2015). 
 
 
Figure 5. Primary care physicians’ ranking of potential negatives associated with 
sharing genomic information with patients. Adapted from Ref. II, Table 5. 
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 4.1.2. Public perspectives 
From 2011 to 2013, the proportion of the public “interested” in genetic testing 
increased from 74% to 87%, while the proportion of “definitely not interested” 
remained at 7–8%. The most common motive for testing throughout the years 
was “So that doctors could give me better advice and monitor my health more 
closely,” with an average of 56% agreeing with this statement. Close to half of 
respondents agreed with all motives for testing listed (Table 1.). The most 
commonly chosen barrier against testing was that the test “Might give me 
unwanted information,” with an average of 41% agreeing with this statement. 
An average of 14% indicated concerns about privacy as a potential barrier 
against genetic testing. 
  In our 2011 survey, we gave participants the following statement: “Imagine 
you have ordered a genetic test. Based on the results, it is possible to consult 
you on your risks for diseases. Who should the test results preferably be sent 
to/shared with: your primary care physician, you, or both?” Most respondents 
would be willing to share the results with their PCP, either alone (14%) or with 
themselves (70%). Only 12% were not willing to share results with their PCP. 
According to a question added to the 2013 and 2014 surveys, most respondents 
preferred to interact with their PCP as the first contact (40%), followed by an 
unspecified specialist (30%), geneticist (25%), other (0%), and difficult to say 
(5%).  
 
 
Table 1.  Estonian public’s motives and barriers for genetic testing* 
 
Motive or barrier 2011 2013 2014 Mean 
On average 77% 
very or fairly 
interested in 
testing 
General curiosity about my 
genetic make-up  
47% 53% 53% 51% 
So that I could change my 
lifestyle and health behavior 
accordingly 
45% 47% 50% 47% 
So that the doctors could give me 
better advice and help regarding 
my health (monitor my health 
more closely) 
56% 56% 55% 56% 
It could be useful for others 
(science, offspring) 
39% 48% 46% 44% 
12% not very and 
8% definitely not 
interested 
Results are not reliable, not all is 
known yet about the genes 
24% 21% 19% 21% 
I am concerned about my privacy 20% 10% 12% 14% 
Results cannot yet be used in 
disease treatments  
20% 16% 23% 20% 
Might give me unwanted 
information  
40% 41% 43% 41% 
*Adapted and modified from (Leitsalu et al. 2012) 
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 In 2015, the Ministry of Social Affairs, with input from the EGCUT, conducted 
a more extensive survey of the public as part of the FSPME (Anon 2015). 
Results for potential barriers against testing were similar to those found in our 
survey. The most commonly raised concern was fear of unwanted/unexpected 
information (53%). Respondents preferred to use their PCP (37%), geneticist 
(29%), other specialist (20%), or web search (4%) for first-line counseling. 
Among all of the respondents who reported having undergone genetic testing, 
79% had done so by participating in the EGCUT and the open-ended comments 
included disappointment about not receiving any feedback from the biobank.  
Results from these surveys can be used for the development of educational 
resources to improve genetic literacy among the general public, to facilitate the 
effective use of genomic information in clinical care, and to avoid any unsound 
effects. Respondents indicated that they had insufficient information about what 
participation in the biobank entails. One of the main fears reported in all of the 
Estonian surveys was the fear of receiving unwanted information. These two 
findings support the need for additional information accompanying the consent 
procedure or continuous dialogue with and education of the public in general. 
On the flip side, most of the public indicated that they are interested in genetic 
testing. 
 
 
4.1.3.Potential approaches for communication  
of findings (Ref. I) 
While the discussion on whether or not to return research results to participants 
has been a topic of debate internationally, in the case of the EGCUT, the 
questions have been how and what to return. How should a population biobank 
with over 50,000 participants approach the preparation of individualized 
feedback to participants? In Ref. I, we discuss implications of two potential 
approaches for this challenge: 
 
1. Public health-based approach – Conditions for feedback will be selected 
based on the perspective of greatest gain for the public health. Prevalent 
conditions causing a high burden on the national health care system 
would be considered first. Not all participants will have something to 
report, which does not necessarily mean that they do not have any 
clinically significant findings. 
2. Individual-based approach – Search for findings to be disclosed starts 
from considering which findings could potentially have the most 
significant impact on the individual’s quality of life. In this case, the 
utility concept considered would be broader and include personalized 
utility. There would be something to report for all participants.  
 
In both approaches, the final selection of findings to be reported would have to 
fulfill the ACA criteria. Both approaches will pose a challenge for the research 
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 institute and will elicit procedural and economic challenges. Besides the 
limitation of not disclosing genealogical information, the Estonian HGRA does 
not specify whether results include aggregate or individual, validated or 
preliminary results. One could ask then, what exactly is meant by the duty to 
provide results? Are there principal differences between a proactive ethical duty 
to offer results and a passive duty to respond positively to requests for results 
getting confused (Miller et al. 2008)? 
In the research context, beneficence is thought to exist at the collective level, 
directed towards future generations; in the clinical context, beneficence is 
thought to be on an individual level (Forsberg et al. 2009; Solberg & Steinsbekk 
2012). The public health-based approach would address one of the biobank’s 
three objectives, namely “to use the results of genetic research to improve 
public health,” but would fail to address the individual’s right to know their 
research results. The individual-based approach, however, would be particularly 
challenging. When the selection of potential findings to be disclosed is not 
limited to a pre-determined list, there is a greater challenge in finding and pre-
paring a collaborative relationship with the necessary medical specialists. 
Additionally, with a wide array of potential findings, informing the participant 
of the potential benefits and harms, and enabling them to make an informed 
decision, are difficult goals. This issue will be discussed in more detail in 
Section 4.2.1. 
The EGCUT is considering implementing a participant portal. Similarly to 
the MyPortal of Nederland’s Twin Registry (Bovenberg et al. 2009), the portal 
would enable participants to see if there is any genotype data generated using 
their sample and what projects their data have been used in. This consideration 
raises the issue of the aspects that participants are interested in. Survey results 
(see Sections 4.1.1 and 4.1.2) indicate that both the public and physicians have 
interest in these data. There is an understanding by participants that they took a 
genetic test when volunteering for the EGCUT and are now waiting for their 
results (Leitsalu et al. 2012; Anon 2015). This perception suggests that at least a 
proportion of participants are expecting individual research results. Thus, 
general information about the type of research conducted and the resulting 
publications may not fulfill their expectations.  
A national personalized medicine project with biobank participants is 
currently in the pilot stage. Based on the public health approach, key areas were 
chosen for the pilot. These include cardiovascular medicine (coronary artery 
disease), endocrinology (type 2 diabetes) and oncology (breast cancer) (Anon 
2015). In parallel, the EGCUT is conducting genotype-based research projects, 
wherein participants have the option to be informed of their individual research 
results. The first of these projects is presented in Sections 4.2.  
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 4.2. Incidental findings and practice 
4.2.1. Development of a procedure  
for return of results (Ref. III and Ref. IV)  
Previously, the phenotype of 16p11.2 deletion and duplication carriers was 
described in clinically ascertained individuals – that is, patients and their 
relatives (Jacquemont et al. 2011). The reverse phenotyping approach, in which 
phenotypes are refined based on genetic marker data (Schulze & McMahon 
2005), can be valuable in elucidating the spectrum of phenotypes associated 
with a particular genomic finding. In 2012, a project was planned to investigate 
the phenotype among population carriers of 16p11.2 deletions and duplications 
without clinical preselection: that is, through reverse-phenotyping among the 
population biobank cohort of the EGCUT (Ref. III).  
The EGCUT has a very thorough, regularly updated database of the pheno-
typic health description of participants. The HGRA and consent form of the 
biobank enable reverse phenotyping through the abilities to link phenotype to 
genotype, and to recontact participants for further investigations (Ref. VI). This 
procedure considers the participants’ rights and interests (Ref. IV). As per the 
HGRA, participants have a right to know or not know their research results and 
to be offered counseling. Prior to the 16p11.2 project, the EGCUT had not 
communicated any individual research findings to participants, and a procedure 
for communicating such findings had not been developed.  
We developed a six-step process of discovery, contact, validation, feedback, 
follow-up, and survey, described in detail in the Methods section and illustrated 
in Figure 1 of Ref. IV. Discovery and validation steps were covered thoroughly 
in Ref. III. The key to this process was having two visits. A new separate 
sample was obtained for independent validation of 16p11.2 CNVs, before 
findings would be disclosed. The most difficult steps were recontacting partici-
pants and obtaining additional consent while not disclosing the incidental finding.  
 
 
4.2.1.1. Recontacting and reconsenting 
Guidelines recommend that the potential of finding incidental findings and the 
options regarding the communication of these findings be incorporated into the 
baseline consent form of prospective studies. Many biobanks have followed 
these recommendations (Keogh et al. 2014; Olson et al. 2013; Crook et al. 
2014; Kaye et al. 2014). As most such guidelines were developed after 2010 
(Knoppers et al. 2015), the situation is complex for datasets that implemented 
their baseline consent forms decades ago (Figure 5.), which is the case for 
EGCUT. Similarly, the broad consent of the EGCUT for unspecified future 
research included only the option to receive feedback and counseling (Ref. VI).  
The situation creates a practical challenge about informed consent: How do 
researchers facilitate the participants to make informed choices when the nature 
of broad consent allows such a wide variety of research to be conducted that 
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 even the researchers cannot predict or specify potential incidental findings? To 
address this question, a separate project-specific consent was prepared. This led 
to another challenge: How do researchers provide sufficient information within 
the specific consent form to enable participants to make an informed decision 
on disclosure of findings, without disclosing too much information? With 
respect to participants’ right to know or not know, we decided that the invitation 
letter should avoid disclosing even a presence of findings. The complete invi-
tation letter and participant information sheet can be found in Supplementary 
materials S1 and S2 of Ref. IV. 
Wolf et al. recommended that researchers must accept participants’ prefe-
rence not to know. However, in the case of a finding associated with a life-
threatening or very serious condition, they recommended that the researcher 
would reconfirm with the participant, stating: “Without revealing the infor-
mation itself, the researchers may try to confirm that the research participant 
indeed wants to refuse even information of high health importance and utility” 
(Wolf et al. 2008). I would challenge this recommendation since it is itself a 
form of disclosure that there is a finding, leaving it up to the participant to 
imagine what the finding could possibly be that makes physicians double-check 
previously made decisions.  
 
 
 
Figure 5. Timeline of key guidelines/proposals regarding the report of incidental 
findings and related events in Estonia.  
 
 
  
35
 4.2.1.2. Counseling and follow-up 
There were several aspects that needed to be considered when counseling the 
participants. These included the fact that they are population biobank partici-
pants and not patients coming to genetic consultation per se; the sensitive nature 
of the phenotypic features associated with the conditions, the phenotypic 
variability of the 16p11.2 deletion and duplication syndromes and the genotype-
to-phenotype approach used to identify the carriers. 
The 16p11.2 deletion and duplication syndromes are both associated with 
psychiatric conditions (Ref. IV, Table 1.) and can be considered particularly 
sensitive, with a potential for stigma and discrimination. On the other hand, 
knowledge of a genetic origin for the psychiatric symptoms can lead to 
awareness that behavior is not a personal character trait but rather a symptom of 
a syndrome (Bortolotti & Widdows 2011). 
The genotype-to-phenotype approach is valuable for describing the pheno-
typic variability of a syndrome. Such study type and the policy for the return of 
results introduce ethical issues because carriers with no apparent phenotype can 
receive an unexpected diagnosis. The seemingly unaffected individuals are of 
particular interest to researchers, but pose a particular challenge in terms of 
genetic counseling. As the phenotype between family members can vary from 
severe to seemingly unaffected it is difficult to give a prognosis and predict the 
severity of the phenotype. These factors may contribute to phenomenon of the 
“worried well”, where unaffected at risk individuals behave or are treated by 
others as if they were ill (Bortolotti & Widdows 2011).  
We offered contact details of a genetic counselor affiliated with the biobank 
for follow-up questions, but there was lack of interest from participants as none 
of them contacted the counselor. Similar results have been reported previously, 
with studies finding that only 10-14% of study subjects took advantage of 
complimentary counseling services (Bloss et al. 2011). Perhaps other means of 
education should be considered. In a study by Townsend et al., participants 
mentioned a wide range of options, with varying degrees of engagement (e.g., 
with professionals and self-education), to increase participants’ knowledge 
(Townsend et al. 2012). Additionally, new communication methods and edu-
cation aids are being developed that apply information and communication 
technologies (Sanderson et al. 2015; Bovenberg et al. 2009; Kaye et al. 2015).  
 
 
4.2.1.3. Identified challenges 
Main challenges in communicating research findings to biobank participants 
identified in this pilot study were procedural and economical, similar to those 
outlined by Keogh et al. and Budin-Ljoesne et al. (Keogh et al. 2014; Budin-
ljøsne et al. 2016). Challenges included a lack of existing protocols, logistics, 
and availability of appropriate healthcare professionals. Costs and burdens 
involved with disclosing research results or incidental findings should be 
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 included in the research budget from the beginning as a cost for performing 
ethical research  (Budin-ljøsne et al. 2016).  
 
 
4.2.2. Interest for disclosure and impact thereof (Ref. IV)  
Previous surveys conducted in Estonia (see Sections 4.1.1 and 4.1.2) investi-
gated stakeholders’ attitudes and the hypothetical effect predicted by the general 
public or physicians. The EGCUT 16p.11.2 project provided an opportunity to 
survey the response to receiving genetic information. Although the number of 
participants was small, participants from the 16p11.2 project were successfully 
recontacted. All nine contacted individuals were interested in participating in 
the project (Ref. IV, Figure 1). Interest for receiving results was evident, with 
all eight participants who were able to participate expressing interest in the 
disclosure of results and counseling. These results are consistent with the results 
of Estonian surveys, which showed high interest for genetic testing. Similarly, 
previous reports showed high interest for receiving genomic research results 
and/or incidental findings in general (Bennette et al. 2013; Bollinger et al. 2012; 
Facio et al. 2013; Meulenkamp et al. 2010) and for genetic testing for condi-
tions involving psychiatric symptoms (Wilde et al. 2010; Jones et al. 2002).  
As the EGCUT was preparing for the first project involving the commu-
nication of genomic findings to participants, a survey was constructed and sent 
to participants who had received an incidental finding. This survey was sent 11–
17 months after finding disclosure. The response rate to the survey was 62.5% 
(5/8 responded), with a similar average age and Full-Scale Intelligence Quotient 
(FSIQ) range among responders and nonresponders (Ref. IV, Table 3.). Indi-
vidual survey responses can be found in Supplementary materials S5 of Ref. IV. 
All five responders had a positive attitude towards being contacted by the 
biobank and having the finding disclosed. Most felt that the information had a 
positive impact on their health care and/or treatment (see Perceived impact in 
Ref. IV, S5). Using a 5-point Likert scale, where 5 is agree and 1 is disagree, 
respondents indicated that the received information was interesting (mean 
response score of 5), informative (4.4), valuable (4.25), and understandable 
(4.2). Similarly to previous reports (O’Neill et al. 2015) a range of emotional 
response was reported. On average, the communication of results made parti-
cipants feel clarity (3.8) and relief (3.6) and did not leave them indifferent 
(1.75). Four of the five participants reported being able to cope. Overall, there 
were no participants who had a completely negative response (Table 2). Two 
participants (Dup2 and Del3), who tended to have more negative responses, still 
reportedly were able to cope, were glad to be contacted, and perceived a posi-
tive change in their treatment or condition. One participant (Dup3) who was not 
able to cope with the finding tended to respond positively to most other ques-
tions. One could argue that the three nonresponders to the survey might be 
representatives of negative response, unfortunately we do not know the reasons 
for not responding. 
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 Table 2. Individual participant responses post disclosure of 16p11.2 CNV carrier status. * 
 Dup1 Dup2 Dup3 Del2 Del3 Mean 
The information provided at the genome center and in the letter on the genetic finding and 
the potential health problems associated with it was:1 
Understandable 5 2 5 5 4 4.2 
Interesting 5 5 5 5 5 5 
Informative 5 4 4 5 4 4.4 
Valuable x 4 4 5 4 4.252 
After being counseled on the health problems associated with the genetic variant I carry 
made me feel…1   
Clarity 5 2 5 5 2 3.8 
Relief 5 2 4 5 2 3.6 
Indifference x 3 2 1 1 1.752 
Confusion x 4 3 1 4 32 
Worry 5 5 2 1 2 3 
For the statement please mark the most appropriate answer1  
I am able to cope with having this 
condition in my family 
5 5 1 5 5 4.2 
I am glad that the genome center 
contacted me about the genetic 
finding 
5 5 5 5 5 5 
I now have better access to health 
care / specialists. 
5 1 4 4 2 3.2 
I feel that my treatment and/or 
condition has improved 
5 4 3 3 5 4 
1 (5 - Agree, 4 - Slightly agree, 3 - Unsure, 2 - Slightly disagree, 1 - Disagree) 
2 Not all 5 respondents answered this question. 
x – unanswered  
Negative responses 
*Table adapted from Ref. IV, S  
 
In the survey, four of the five respondents reported having an appointment with 
their PCP. Two participants had an appointment with a specialist, as per our 
recommendations (Ref. IV, Table S3). Although only one person reported 
changes in their treatment made by physicians, all participants felt that they had 
better access to healthcare or that their condition/treatment had improved (Table 
2). Our finding that the participants seemed to value additional factors besides 
those with clinical implications is consistent with previous studies (Lewis et al. 
2016; Lupo et al. 2016). This supports the standpoint that the utility should be 
considered in a broader context and that guidelines based on ACA criteria may 
be too restrictive (Bollinger et al. 2012; Townsend et al. 2012).  
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 4.2.3. Future projects 
Due to the small sample size in this study, the findings are not expected to be 
generalizable. However, they provide evidence to inform establishing a frame-
work for returning incidental findings to research participants. The HGRA, 
EGCUT broad consent, and the developed framework make it possible for the 
EGCUT to conduct much needed empirical research on the impact of genomic 
findings. In 2016, the EGCUT continued recontacting on a case-by-case basis, 
considering the ACMG list as the starting point. Having learned from the pilot 
project (Ref. IV), we have improved the consent form, and altered survey 
methods to include immediate response and long-term follow-up with pre-
viously validated survey instruments. Predisclosure counseling and evaluations 
are planned for the first meeting, and results to be communicated at the second 
meeting, and contact with healthcare specialists is established prior to initiation 
of recontacting.   
In 2015, the Ministry of Social Affairs asked the Government of Estonia to 
carry out a Pilot Project on Personalised Medicine for 2015–2018. The goal of 
the pilot, as per the proposal, is “to implement personalised medicine principles 
into Estonian health care system and to create innovative computerized 
infrastructure for research and development of better targeted methods for 
health care and disease prevention.” (Anon 2015). The pilot project involves 
incorporating genomic information of the EGCUT cohort in the national health 
information system. These plans highlight the importance and need for studies 
on stakeholders’ attitudes, on the impact and utility of reporting genomic 
findings, and on analyzing procedural frameworks for communicating genomic 
findings to research participants and patients.  
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 5. CONCLUSIONS 
I put forward four questions concerning incidental findings in the Introduction. 
My thesis provides the following answers to these questions as conclusions that 
arose from the work performed: 
1. Should incidental findings be disclosed to research participants? 
PCPs and the public have expressed an eagerness for the EGCUT to disclose 
results. 
2. How much and what information should be disclosed? 
Theoretical attitudes of PCPs and responses to actual results from biobank 
participants are more liberal than existing guidelines for the return of 
incidental findings. 
3. What is the optimal procedure for communicating incidental findings in a 
research practice? 
We developed a procedure for the disclosure of incidental findings to 
research participants of a population biobank. 
4. What is the impact of disclosed information? 
Respondents indicated a positive attitude towards receiving results, even 
results associated with psychiatric symptoms and those with limited 
actionability. Moreover, disclosure was shown to impose low distress. 
Existing guidelines limit the scope of data for disclosure to findings that have 
clear implications on the participant’s clinical management. This thesis adds to 
the increasing body of evidence that participants are interested in information, 
even findings that do not have clinical significance or actionability, as some 
results can be personally meaningful. Our results support the recommendation 
of Shalowitz and Miller (Shalowitz & Miller 2005) to consider the “meaningful 
information” that research participants may be interested in in a broader 
context. Our developed framework was appreciated by participants and can be 
applied in future projects. 
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 SUMMARY IN ESTONIAN  
Genoomsete teadustöötulemuste tagasiside 
populatsioonipõhise biopanga geenidoonoritele 
Iga inimgenoomi järjestus sisaldab hinnanguliselt kümmet kuni viitkümmet tõe-
näoliselt patogeenset variatsiooni, millest kuni viis võivad olla kliiniliselt oluli-
sused. Ülegenoomsete meetodite kasutamine teadustöös suurendab tõenäosust 
avastada nn juhuleide, mis on küll tavaliselt väljaspool konkreetse uuringu ees-
märke, kuid siiski kliiniliselt olulised. Laialdane genoomiandmete genereeri-
mine tekitab vajaduse juhiste järele, mis suunaks ja ühtlustaks juhuleidude 
käsitlust, vastates küsimustele – kuidas peaks ootamatult tuvastatud kliiniliselt 
olulise leiu puhul käituma, millistel juhtudel on uuritava isiku informeerimine 
õigustatud ja kuidas peaks kommunikatsioon toimuma. Seejuures tuleb arves-
tada teadustöö üldisi eesmärke, ressursse ning uuritavate huve ja õigusi. 
Tõenduspõhiste juhiste loomine eeldab avalikku arutelu, empiirilisi uuringuid 
huvirühmade suhtumise kaardistamiseks, samuti tagasiside meetodite analüüsi 
ning uuringuid juhuleidudest informeerimise mõjust osalejatele. Käesolev töö 
loob nende juhiste koostamise lähtealused. 
Töö tulemustest järeldub, et nii perearstide kui rahva seas on huvi geneetilise 
informatsiooni vastu. Senised juhised keskenduvad tagasiside andmisel eelkõige 
kliiniliselt olulistele ja sekkumistõhusatele leidudele. Perearstide hoiakud ja 
Geenivaramu uuritavate hinnangud geneetilise informatsiooni suhtes osutusid 
liberaalsemateks kui olemasolevad soovitused ja juhised. Käesolev töö lisab 
tõendeid, et uuritavad hindavad geneetilise informatsiooni juures lisaks kliinilis-
tele kaalutlustele ka muid faktoreid.  
Töö käigus loodi meetod juhuleidude raporteerimiseks Geenivaramu doono-
ritele, mis on vastavuses Inimgeeniuuringute seaduse ja olemasolevate juhis-
tega. Uuritavate vastukaja tagasiside osas oli positiivne isegi psühhiaatriliste 
sümptomitega seostatud ning piiratud sekkumistõhususega leidude puhul. 
Väljatöötatud meetod on kasutusel järgmistes Geenivaramu projektides, mis 
hõlmavad tagasiside andmist geenidoonoritele.  
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